Disease-related malnutrition in outpatients with systemic sclerosis

Clinical Nutrition

Volumn 31, Issue 5, 2012, Pages 666-671

  Caporali, Roberto ^a   Caccialanza, Riccardo ^b   Bonino, Claudia ^a   Klersy, Catherine ^b   Cereda, Emanuele ^b   Xoxi, Blerina ^a   Crippa, Anna ^b   Rava, Maria Luisa ^b   Orlandi, Margherita ^b   Bonardi, Chiara ^b   Cameletti, Barbara ^b   Codullo, Veronica ^a   Montecucco, Carlomaurizio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Disease activity; Malnutrition; Systemic sclerosis

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOSUPPRESSIVE AGENT; PREALBUMIN; STEROID;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; DIARRHEA; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL DISEASE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; OUTPATIENT; PREVALENCE; SYSTEMIC SCLEROSIS; WEIGHT REDUCTION;

AGED; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; LOGISTIC MODELS; MALE; MALNUTRITION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITION ASSESSMENT; OUTPATIENTS; PREALBUMIN; PREVALENCE; SCLERODERMA, SYSTEMIC;

EID: 84866621665     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2012.02.010     Document Type: Article

References (40)

1. Norman K., Pichard C., Lochs H., Pirlich M. Prognostic impact of disease-related malnutrition. Clin Nutr 2008, 27(1):5-15.
2. Akner G., Cederholm T. Treatment of protein-energy malnutrition in chronic nonmalignant disorders. Am J Clin Nutr 2001 Jul, 74(1):6-24.
3. Caccialanza R., Klersy C., Cereda E., Cameletti B., Bonoldi A., Bonardi C., et al. Nutritional parameters associated with prolonged hospitalization in ambulatory adult patients. CMAJ 2010, [Epub ahead of print].
4. Cohen S. The gastrointestinal manifestations of scleroderma: pathogenesis and management. Gastroenterology 1980 Jul, 79(1):155-166.
5. Akesson A., Gustafson T., Wollheim F., Brismar J. Esophageal dysfunction and radionuclide transit in progressive SSc. Scand J Rheumatol 1987, 16(4):291-299.
6. Merlo A., Cohen S. Swallowing disorders. Annu Rev Med 1988, 39:17-28.
7. Akesson A., Wollheim F.A. Organ manifestations in 100 patients with progressive SSc: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989 Aug, 28(4):281-286.
8. King C.E., Toskes P.P. Small intestine bacterial overgrowth. Gastroenterology 1979 May, 76(5 Pt. 1):1035-1055.
9. Vilter R.W., Bozian R.C., Hess E.V., Zellner D.C., Petering H.G. Manifestations of copper deficiency in a patient with SSc on intravenous hyperalimentation. N Engl J Med 1974 Jul 25, 291(4):188-191.
10. Grabowski G., Grant J.P. Nutritional support in patients with systemic scleroderma. J Parenter Enteral Nutr 1989 Mar-Apr, 13(2):147-151.
11. Akesson A., Akesson B., Gustafson T., Wollheim F. Gastrointestinal function in patients with progressive SSc. Clin Rheumatol 1985 Dec, 4(4):441-448.
12. Baron M., Hudson M., Steele R., Canadian Scleroderma Research Group Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. J Rheumatol 2009 Dec, 36(12):2737-2743.
13. Krause L., Becker M.O., Brueckner C.S., Bellinghausen C.J., Becker C., Schneider U., et al. Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis. Ann Rheum Dis 2010 Nov, 69(11):1951-1957.
14. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
15. Furst D.E., Clements P.J., Steen V.D., Medsger T.A., Masi A.T., D'Angelo W.A., et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998 Jan, 25(1):84-88.
16. Valentini G., Della Rossa A., Bombardieri S., Bencivelli W., Silman A.J., D'Angelo S., et al. European multicentre study to define disease activity criteria for SSc. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001 Jun, 60(6):592-598.
17. Medsger T.A., Bombardieri S., Czirjak L., Scorza R., Della Rossa A., Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003, 21(3 Suppl. 29):S42-S46.
18. Clements P.J., Becvar R., Drosos A.A., Ghattas L., Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003, 21(3 Suppl. 29):S15-S18.
19. Walker U.A., Tyndall A., Czirják L., Denton C., Farge-Bancel D., Kowal-Bielecka O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 2007, 66:754-763.
20. Poole J.L., Steen V.D. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991, 4:27-31.
21. World Health Organization Physical status: the use and interpretation of anthropometry. Report of a WHO expert committee. World Health Organ Tech Rep Ser 1995, 854:1-452.
22. Caccialanza R., Palladini G., Klersy C., Cena H., Vagia C., Cameletti B., et al. Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1. Am J Clin Nutr 2006, 83(2):350-354.
23. Harris J.A., Benedict F.G. Biometric studies of basal metabolism in man 1919, Carnegie Institute of Washington, Washington, DC.
24. Carnovale E., Marletta L. Tabelle di composizione degli alimenti. Istituto Nazionale di Ricerca per gli Alimenti e la Nutrizione 2000, EDRA Press, Roma.
25. Kondrup J., Allison S.P., Elia M., Vellas B., Plauth M., Educational and Clinical Practice Committee, European Society of Parenteral and Enteral Nutrition (ESPEN) ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003, 22:415-421.
26. Baron M., Bernier P., Côté L.F., Delegge M.H., Falovitch G., Friedman G., et al. Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clin Exp Rheumatol 2010 Mar-Apr, 28(2 Suppl. 58):S42-S46.
27. James W.P., Francois P.J. The choice of cut-off point for distinguishing normal body weights from underweight or 'chronic energy deficiency' in adults. Eur J Clin Nutr 1994, 48(Suppl. 3):S179-S184.
28. Lamprecht P. TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases. Autoimmun Rev 2005 Jan, 4(1):28-34.
29. Arends J., Bodoky G., Bozzetti F., Fearon K., Muscaritoli M., Selga G., et al. ESPEN Guidelines on enteral nutrition: non-surgical oncology. Clin Nutr 2006, 25:245-259.
30. Muscaritoli M., Anker S.D., Argilés J., Aversa Z., Bauer J.M., Biolo G., et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr 2010, 29:154-159.
31. Bozzetti F. Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 2009 Mar, 17(3):279-284. SCRINIO Working Group.
32. Ingenbleek Y., Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr 1994, 14:495-533.
33. Myron Johnson A., Merlini G., Sheldon J., Ichihara K. Scientific Division Committee on Plasma Proteins (C-PP), International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med 2007, 45(3):419-426.
34. Devakonda A., George L., Raoof S., Esan A., Saleh A., Bernstein L.H. Transthyretin as a marker to predict outcome in critically ill patients. Clin Biochem 2008, 41(14-15):1126-1130.
35. Herrick A.L., Worthington H., Rieley F., Clarke D., Schofield D., Braganza J.M., et al. Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol 1996 Apr, 23(4):650-653.
36. Lundberg A.C., Akesson A., Akesson B. Dietary intake and nutritional status in patients with SSc. Ann Rheum Dis 1992 Oct, 51(10):1143-1148.
37. Khanna D., Hays R.D., Maranian P., Seibold J.R., Impens A., Mayes M.D., et al. Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Rheum 2009, 61:1257-1263.
38. Baron M., Hudson M., Steele R., Lo E. Validation of the UCLA scleroderma clinical trial gastrointestinal tract instrument version 2.0 for systemic sclerosis. J Rheumatol 2011, 38:1925-1930. the Canadian Scleroderma Research Group.
39. Bae S., Allanore Y., Coustet B., Maranian P., Khanna D. Development and validation of French version of the UCLA scleroderma clinical trial consortium gastrointestinal tract instrument. Clin Exp Rheum 2011, 29:S15-S21.
40. Kowal-Bielecka O., Landewé R., Avouac J., Chwiesko S., Miniati I., Czirjak L., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR). Ann Rheum Dis 2009, 68:620-628.